---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-003868"
form_type: "8-K"
ticker: "NDRA"
cik: "0001681682"
company_name: "ENDRA Life Sciences Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T06:15:13.404329+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ENDRA Q4 net loss $1.5M, FDA De Novo review ongoing; Q2 meeting set

## Summary
- Net loss Q4 2023: $1.5M ($0.17/share) vs $3.3M ($1.04) in Q4 2022.
- Full year 2023 net loss $10.1M ($1.58/share) vs $13.2M ($4.56) in 2022.
- Cash and cash equivalents $2.8M as of December 31, 2023.
- Installed first TAEUS system at King's College Hospital UK for 75-subject clinical study.
- FDA De Novo review ongoing; in-person meeting scheduled for Q2 2024 after Additional Information request.

## SEC filing metadata
- accession: 0001654954-24-003868
- form_type: 8-K
- ticker: NDRA
- cik: 0001681682
- company_name: ENDRA Life Sciences Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681682/000165495424003868/0001654954-24-003868-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681682/000165495424003868/ndra_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-003868
- JSON: https://secwatch.observer/filing/0001654954-24-003868.json
- Plain text: https://secwatch.observer/filing/0001654954-24-003868.txt

## Key facts
- Earnings Releases
  ENDRA Life Sciences Inc. reported the quarter and year ended December 31, 2023 results: net income Net loss in the fourth quarter of 2023 was $1.5 million, or $0.17 per share, EPS $0.17 per share.
  - Period: the quarter and year ended December 31, 2023
  - Net income: Net loss in the fourth quarter of 2023 was $1.5 million, or $0.17 per share
  - EPS: $0.17 per share
  - Result: reported results
  source text: Net loss in the fourth quarter of 2023 was $1.5 million, or $0.17 per share, compared with a net loss of $3.3 million, or $1.04 per share, in the fourth quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1681682/000165495424003868/0001654954-24-003868-index.htm
- Earnings Releases
  ENDRA Life Sciences Inc. reported the year ended December 31, 2023 results: net income Net loss in 2023 was $10.1 million, or $1.58 per share, EPS $1.58 per share.
  - Period: the year ended December 31, 2023
  - Net income: Net loss in 2023 was $10.1 million, or $1.58 per share
  - EPS: $1.58 per share
  - Result: reported results
  source text: Net loss in 2023 was $10.1 million, or $1.58 per share, compared with a net loss of $13.2 million, or $4.56 per share, in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1681682/000165495424003868/0001654954-24-003868-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.